Stratos Genomics closes Series-A financing deal

NewsGuard 100/100 Score

Stratos Genomics Inc. today announced it has closed a Series-A financing deal of $4 million to continue development of its ultra-low-cost nucleic acid sequencing method for whole genome analysis and molecular diagnostics. The round was led by Fisk Ventures and included Stratos Group LLC.

"In the midst of the current, highly-charged genomic sequencing market, this investment in Stratos Genomics is an important statement. It indicates not only the validity of the technology but confidence in our future success," Stratos Genomics CEO, Allan Stephan, said. "We are pleased to have the support of Fisk Ventures as we continue developing technology that will play an important role in the future of medicine and genomic sciences."

"The Stratos Genomics technology has the potential to revolutionize personalized medicine and bring genome sequencing technology to all. If our goals are realized, Stratos Genomics will have a huge impact on life sciences," Stephen Rose, Managing Director of Fisk Ventures, said.


Stratos Genomics Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Baylor study reveals role of newly inherited DNA variants in recessive diseases